Chemotherapy agents and timing of chemotherapy in prostate cancer management

被引：2

作者：

Donohue K.M. ^{[1
]}

Petrylak D.P. ^{[1
]}

机构：

[1] Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, 10032, NY

来源：

Current Urology Reports | 2005年 / 6卷 / 3期

关键词：

Clin Oncol; Docetaxel; Estramustine; Mitoxantrone; Prostate Cancer;

D O I：

10.1007/s11934-005-0011-8

中图分类号：

学科分类号：

摘要：

In 2005, it is estimated that more than 30,000 men will die from metastatic hormone-refractory prostate cancer. For decades, no chemotherapeutic agent demonstrated a survival benefit in these patients, although two randomized clinical trials demonstrated a clear palliative benefit using mitoxantrone combined with a corticosteroid. However, beginning in 1999, a series of phase-2 trials were performed using docetaxel, either as a single agent or in combination with estramustine. Preliminary data implied a survival improvement, with median survivals reported to be 14 to 23 months. Prostate-specific antigen levels dropped by more than 50% in 38% to 48% of patients treated with docetaxel. These findings were confirmed in two phase-3 randomized trials in which docetaxel with and without estramustine have demonstrated a survival benefit using chemotherapy in the treatment of hormone-refractory prostate cancer. © 2005, Current Science Inc.

引用

页码：224 / 227

页数：3

共 23 条

[1]

Jemal A., Murray T., Ward E., Et al., Cancer Statistics 2005, Can J Clin, 55, pp. 10-30, (2005)

[2]

Smaletz O., Scher H.I., Small E.J., Et al., Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration, J Clin Oncol, 20, pp. 3972-3982, (2002)

[3]

Yagoda A., Petrylak D., Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer, Cancer, 3, pp. 1098-1099, (1993)

[4]

George D., Kantoff P., Prognostic indicators in hormone refractory prostate cancer, Urol Clin North Am, 26, pp. 303-310, (1999)

[5]

Petrylak D., Scher H., Li Z., Et al., Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostate cancer treated with single agent chemotherapy, Cancer, 70, pp. 2870-2878, (1992)

[6]

D'Amico A., Saegaert T., Chen M., Et al., Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate-specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer, Cancer, 95, pp. 275-280, (1992)

[7]

Fazzari M., Heller G., Scher H.I., The phase 2/3 transition: toward the proof of efficacy in cancer clinical trials, Control Clin Trials, 21, pp. 360-368, (2000)

[8]

Scher H.I., Eisenberger M., D'Amico A., Et al., Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol, 22, pp. 537-556, (2004)

[9]

Tannock I., Osoba D., Stockler M., Et al., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol, 14, pp. 1756-1764, (1996)

[10]

Kantoff P., Halabi S., Conaway M., Et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study, J Clin Oncol, 17, pp. 2506-2513, (1999)

← 1 2 3 →